Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 6/20 | 1.00 |
| ▸ | GABBR1 | Q9UBS5 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
| ▸ | DRD3 | P35462 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | THRB | P10828 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenibut SCHEMBL9545047 | 1.00 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP2C19 | |
| Phenibut SCHEMBL351501 | 1.00 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP2C19 | |
| Phenibut SCHEMBL22831453 | 0.98 | GABBR2 (0.96) | GABBR2GABBR1LMNACYP2C9CYP2C19 | |
| Phenibut SCHEMBL3053795 | 0.98 | GABBR2 (0.96) | GABBR2GABBR1LMNACYP2C9CYP2C19 | |
| Phenibut SCHEMBL27912811 | 0.96 | GABBR2 (0.92) | GABBR2GABBR1LMNACYP2C9CYP2C19 | |
| Phenibut SCHEMBL28119792 | 0.94 | GABBR2 (0.89) | GABBR2GABBR1LMNACYP2C9CYP2C19 | |
| SCHEMBL503819 | 0.87 | GABBR2 (0.76) | GABBR2GABBR1LMNACYP2C9CYP2C19 | |
| SCHEMBL27691658 | 0.86 | GABBR2 (0.75) | GABBR2GABBR1LMNACYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL7092228 | 0.85 | GABBR2 (0.73) | GABBR2GABBR1LMNACYP2C9CYP2C19 | |
| SCHEMBL6734410 | 0.85 | GABBR2 (0.73) | GABBR2GABBR1LMNACYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1062 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12578348-B2 | Blood indicators of Alzheimer's disease | THE INSTITUTE FOR ETHNOMEDICINE (US) | 2026-03-17 | — | — | US | claimed |
| US-20260000726-A1 | Synergistic Herbal Compositions for Pain Management and Opioid Use Reduction | PFOHL JEFFREY L (US) | 2026-01-01 | — | — | US | claimed |
| US-20250382671-A1 | METHODS OF DETECTION AND ANALYSIS OF NUCLEIC ACID IN CIRCULATING BODILY FLUIDS | Brain Chemistry Labs (US) | 2025-12-18 | — | — | US | claimed |
| US-20250375429-A1 | OBLIGATE PAIRING OF ORTHOSTERIC AND NON-ORTHOSTERIC GABA LIGANDS IN PHARMACEUTICAL FORMULATIONS | SMARTER NOT HARDER, INC. (US) | 2025-12-11 | — | — | US | claimed |
| EP-4633638-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | Luminous Mind Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| US-20250228772-A1 | DRUG DELIVERY SYSTEM COMPRISING A REFLUX INHIBITOR FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES | ESOCAP AG (CH) | 2025-07-17 | — | — | US | claimed |
| US-20250186401-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND A2 ADRENERGIC RECEPTORS PROVIDES RELIEF FROM STRESS INDUCED DEPRESSION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2025-06-12 | — | — | US | claimed |
| CN-120025976-A | Method for differentiating hematopoietic stem/progenitor cells into granulocytes | 苏州血霁生物科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| US-20250163379-A1 | METHOD FOR DIFFERENTIATING HEMATOPOIETIC STEM/PROGENITOR CELLS INTO NK CELLS | HEMACELL BIOTECHNOLOGY INC. (CN) | 2025-05-22 | — | — | US | claimed |
| EP-4536194-A1 | DRUG DELIVERY SYSTEM COMPRISING A REFLUX INHIBITOR FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES | EsoCap AG (CH) | 2025-04-16 | — | — | EP | claimed |
| WO-2004105795-A1 | PHARMACEUTICAL COMBINATIONS OF A PROTON PUMP INHIBITOR AND A COMPOUND WHICH MODIFIES GASTROINTESTINAL MOTILITY | ALTANA PHARMA AG (DE) | 2004-12-09 | — | — | WO | claimed |
| WO-2004012762-A2 | METHOD AND COMPOSITION FOR PROTECTING NEURONAL TISSUE FROM DAMAGE INDUCED BY ELEVATED GLUTAMATE LEVELS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2004-02-12 | — | — | WO | claimed |
| EP-0936906-B1 | REFLUX INHIBITORS | ASTRAZENECA AB (SE) | 2003-09-10 | — | — | EP | claimed |
| US-20030162754-A1 | Use of GABA and GABAB agonists | TUFTS UNIVERSITY | 2003-08-28 | — | — | US | claimed |
| US-6117908-A | Use of GABAB receptor agonists as reflux inhibitors | ASTRA AKTIEBOLAG (SE) | 2000-09-12 | — | — | US | claimed |
| WO-1996011680-A2 | USE OF GABA AGONISTS IN THE TREATMENT OF EMESIS | GLAXO GROUP LIMITED (GB) | 1996-04-25 | — | — | WO | claimed |
| EP-0023192-B1 | CYCLOPEPTIDES AND PHARMACEUTICAL PREPARATIONS THEREOF, PROCESS FOR THEIR PREPARATION AND THEIR USE | CIBA-GEIGY AG (CH) | 1984-03-28 | — | — | EP | claimed |
| EP-0051278-A1 | Soft tertiary amine esters of bio-affecting carboxylic acids, processes for preparing and a pharmaceutical composition containing the same | MERCK & CO. INC. (US) | 1982-05-12 | — | — | EP | claimed |
| US-4328214-A | OCTAPEPTIDES, ANTIDIABETICS, TREATING BLOOD LOSSES IN GASTROINTESTINAL TRACT | CIBA-GEIGY CORPORATION (US) | 1982-05-04 | — | — | US | claimed |
| US-3947492-A | Process for producing β-phenyl-γ-amino butyric acid hydrochloride | PEREKALIN VSEVOLOD VASILIEVICH | 1976-03-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250228772-A1 | DRUG DELIVERY SYSTEM COMPRISING A REFLUX INHIBITOR FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES | HSPA5, MLNR, HRH2 | GABBR2 475/4885GABBR1 790/4885LMNA 1353/4885 |
| US-20260000726-A1 | Synergistic Herbal Compositions for Pain Management and Opioid Use Reduction | OPRK1, OPRM1, OPRD1 | GABBR2 73/4885GABBR1 61/4885LMNA 3204/4885 |
| US-20250186401-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND A2 ADRENERGIC RECEPTORS PROVIDES RELIEF FROM STRESS INDUCED DEPRESSION | GABRB2, GABRB1, ADRB2 | GABBR2 13/4885GABBR1 19/4885LMNA 2696/4885 |
| US-12578348-B2 | Blood indicators of Alzheimer's disease | COMT, MAOB, ACHE | GABBR2 137/4885GABBR1 94/4885LMNA 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.